BSBE(SZ:300406) Xin Lang Cai Jing·2025-10-29 01:44Core Insights - The company reported a total revenue of 1.012 billion yuan for Q3 2025, a decrease of 226 million yuan or 18.24% year-on-year [1] - The net profit attributable to shareholders was 272 million yuan, down by 101 million yuan or 27.03% compared to the same period last year [1] - The net cash inflow from operating activities increased by 23.56 million yuan, achieving a 5-year consecutive increase, with a year-on-year growth of 5.84% [1] Financial Performance - The latest debt-to-asset ratio is 24.55%, ranking 51st among peers, with a decrease of 0.61 percentage points from the previous quarter and a decrease of 2.80 percentage points year-on-year [3] - The latest gross profit margin is 79.86%, ranking 4th among peers, with an increase of 0.27 percentage points from the previous quarter and an increase of 2.05 percentage points year-on-year [3] - The latest return on equity (ROE) is 6.81%, ranking 22nd among peers, with a decrease of 2.59 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.46 yuan, ranking 27th among peers, down by 0.17 yuan or 26.98% year-on-year [3] Operational Efficiency - The latest total asset turnover ratio is 0.19 times, ranking 57th among peers, with a decrease of 0.05 times year-on-year, representing a decline of 20.03% [3] - The latest inventory turnover ratio is 0.93 times, ranking 58th among peers, with a decrease of 0.24 times year-on-year, representing a decline of 20.69% [3] Shareholder Structure - The number of shareholders is 18,100, with the top ten shareholders holding 387 million shares, accounting for 65.93% of the total share capital [3] - The largest shareholder is China Medical Investment Co., Ltd., holding 18.49% of the shares [3]